



Inflation Reduction Act Impacts Cost Sharing for Medicare Part B Drugs

Beginning April 1, 2023, in accordance with §11101 and §11407 of the Inflation Reduction Act (IRA, P.L. 117-169):*

- Coinsurance for Part B rebatable drugs will be reduced if the drug's price has increased at a rate faster than the rate of inflation.
- Part B rebatable drugs may be in the following categories: chemotherapy administration services to include chemotherapy/radiation drugs or other drugs covered under Part B of original Medicare, as listed in § 422.100(j)(1)(i).
- The list of Part B rebatable drugs, as well as the effective beneficiary coinsurance for those drugs, could change each quarter. Applicable changes will be calculated based on quarterly pricing files published by CMS and posted to their website.

If you have any questions, please call Healthfirst Provider Services at **1-888-801-1660**, Monday to Friday, 8:30am–5:30pm.

* www.cms.gov/newsroom/press-releases/inflation-reduction-act-tamps-down-prescription-drug-price-increases-above-inflation